Findings reveal a shift from an innate inflammatory immune landscape toward adaptive cytotoxic and immunoregulatory remodeling associated with African genetic similarity in MM.
Abstract
The bone marrow immune microenvironment (BMME) is a critical factor in multiple myeloma (MM) pathogenesis. Despite higher incidence of MM among self-identified African Americans, the relationship between African genetic similarity and the BMME remains unclear. We present the largest analysis to date assessing the impact of Ancestry on the BMME in myeloma (N=320, including 64 with ≥50% African genetic similarity, AFR-High) leveraging our recently generated Immune Atlas. AFR-High was associated with enrichment of late T-effector cells, driven by rare cytotoxic CD4⁺ T cells, suggesting a distinct adaptive BMME. AFR-High exhibited expansion of late-differentiated adaptive NK cells with high cytotoxic GNLY and GZMH expression. AFR-High depicted reduced CD14⁺ monocytes, increased CD16⁺ non-classical monocytes, and expansion of macrophage-like monocyte populations with enrichment of metabolic adaptation, efferocytosis and phagocytic clearance programs, and immunoregulatory pathways. These findings reveal a shift from an innate inflammatory immune landscape toward adaptive cytotoxic and immunoregulatory remodeling associated with African genetic similarity in MM.
The mechanisms underlying immune dysregulation in MM are discussed, recent discoveries regarding immune remodeling associated with clinical outcomes are summarized, and the translational implications of immune-based biomarkers and therapeutic strategies are explored.
Maria P. Ghirardi, Patrícia Brandalise, M. Berraondo et al.· Immuno· 0 citations
The immune tumor microenvironment (iTME) plays a crucial role in disease biology of plasma cell (PC) dyscrasias, but remains poorly characterized in self-identified Black individuals, a population at increased risk. Mass cytometry and scRNA-seq of 128 bone marrow aspirates revealed significant changes in immune cell co...
Hong-Wei Tang, William C. Pilcher, Hui-Huang Yan et al.· Blood· 0 citations
Multiple myeloma (MM) is the second most common blood cancer in the United States. The American Cancer Society projected 36,110 new cases and 20,150 deaths in 2025, 15,850 of them in men, compared with 5,780 in women. Despite this persistent and unexplained incidence and mortality gap favoring women, no mechanism...
Olasunkanmi S. Omojokun, Cameron J. Smith, D. Wusiman et al.· Cancer Epidemiology, Biomark...· 0 citations
Summary Despite widespread immunophenotyping in acute myeloid leukemia (AML), its immunophenotypic heterogeneity remains incompletely understood. Here, we applied state-of-the-art computational modeling to >50 million single cells from diagnostic bone marrow aspirates of 502 AML patients. Jointly modeling leukemic and...
T. Mocking, T. Reuvekamp, Lukas H. Haaksma et al.· iScience· 0 citations
Classic Hodgkin lymphoma (cHL) is a unique B-cell malignancy characterized by a small number of malignant Hodgkin and Reed-Sternberg (HRS) cells embedded within an extensive and highly organized inflammatory microenvironment. Recent studies have highlighted that the biological behavior of cHL is largely determined by d...
A. Carbone, A. Gloghini, Saira S. Ahmed et al.· Blood reviews· 0 citations
The mechanisms governing MDSCs interactions within the myeloma TME are elucidated, potential therapeutic strategies targeting MDSCs are discussed, and a rational framework for integrating MDSC-directed approaches with current MM therapies and immunotherapy is outlined.
Jing-Jing Wen, Qiao-Lin Zhou, Jing Yue et al.· Frontiers in Immunology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.